Mycotopia Therapies entered into a term sheet to acquire 20/20 Global, Inc. (OTCPK:TWGL) for $0.35 million in a reverse merger transaction on November 28, 2020. Mycotopia Therapies entered into definitive agreement to acquire 20/20 Global, Inc. in a reverse merger transaction on December 24, 2020. Ehave, Inc.'s Board of directors has elected to sell 100% of its Mycotopia Therapies subsidiary for $0.35 million to 20/20 Global Inc. while simultaneously acquiring approximately 75.77% of 20/20 Global's outstanding shares from 20/20 Global's management. Ehave has also transferred its 10% interest in PsychedeliTech Inc. and as a subsidiary of 20/20 Global, Mycotopia Therapies will own 10% PsyTech. Ehave Chairman and Chief Executive Officer Ben Kaplan will be named as Chairman and Chief Executive Officer of 20/20 Global, with the current 20/20 Global board stepping down upon completion of all regulatory requirements. Ben Kaplan will remain Chairman and Chief Executive Officer of Ehave. In addition to the appointment of Ben Kaplan as Chairman and Chief Executive Officer of 20/20 Global, Jamaican investment banker, Mark Croskery, will also serve on the Board of 20/20. Under the change of control and funding agreement, Mark D. Williams and Colin Gibson will resign as Officers and Directors. This agreement also provides for Benjamin Kaplan to serve as president of 20/20 Global. The transaction is expected to close January 4, 2021. As of January 4, 2021, 20/20 Global, Inc. entered into an amendment to the agreement to extend the closing date to a mutually agreeable date after completion of the audited financial statements of Mycotopia Therapies Inc.

Terrell W. Smith of Michael Best & Friedrich LLP acted as legal advisor to 20/20 Global and Jonathan D. Leinwand of Jonathan D. Leinwand, P.A acted as legal advisor to EHAVE, Inc. (OTCPK:EHVV.F). Colonial Stock Transfer Company, Inc. acted as transfer agent to 20/20 Global.